Episodic Migraine Therapeutics
1. Qulipta patent expiration
Treatment: Preventive treatment of migraine in adults; Preventive treatment of migraine in adults undergoing concurrent treatment with a strong cyp3a4 inhibitor; Preventive treatment of migraine in adults with s...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9499545 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Nov, 2031
(5 years from now) | |
| US8754096 | ABBVIE | Piperidinone carboxamide azaindane CGRP receptor antagonists |
Jul, 2032
(6 years from now) | |
| US9850246 | ABBVIE | Process for making CGRP receptor antagonists |
Mar, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12383545 | ABBVIE | NA |
Jun, 2039
(13 years from now) | |
| US12090148 | ABBVIE | Treatment of migraine |
Jul, 2041
(15 years from now) | |
| US12350259 | ABBVIE | NA |
Feb, 2043
(17 years from now) | |
| US12465598 | ABBVIE | NA |
Sep, 2042
(16 years from now) | |
| US10117836 | ABBVIE | Tablet formulation for CGRP active compounds |
Jan, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-909) | Apr 17, 2026 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2026 |
Drugs and Companies using ATOGEPANT ingredient
NCE-1 date: 28 September, 2025
Market Authorisation Date: 28 September, 2021
Dosage: TABLET
More Information on Dosage
QULIPTA family patents
